Union Therapeutics strikes million-dollar deal with Chinese partner
The drug orismilast, intended to treat different dermatological disorders, and which Union Therapeutics bought from Leo Pharma last year, is now the basis of an agreement worth millions of US dollars for the Danish biotech company.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY DANIEL PEDERSEN
When the drug orismilast comes to China, the biotech company Union Therapeutics, headquartered in Denmark, will collaborate with Innovent Biologics, informs the Danish company in a press release.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Utility Therapeutics prepares FDA application
For subscribers
